SCHEMBL15312859

SCHEMBL15312859

N=C1NC(=O)/C(=C\c2cn(Cc3ccc(-c4ccccc4[N+](=O)[O-])o3)c(=O)[nH]c2=O)S1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.61
INSR P06213 1/20 0.49
IGF1R P08069 1/20 0.49
GSK3A P49840 6/20 0.47
GSK3B P49841 6/20 0.47
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CG P48736 1/20 0.40
TDP2 O95551 1/20 0.40
CASP7 P55210 1/20 0.40
CASP9 P55211 1/20 0.40
CASP6 P55212 1/20 0.40
CASP8 Q14790 1/20 0.40
BRAF P15056 1/20 0.39
IL33 O95760 2/20 0.39
XDH P47989 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15312858 1.00 CDK2 (0.61) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL623099 0.82 IL33 (0.43) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL10118538 0.80 CDK2 (0.49) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL10118581 0.77 IL33 (0.44) CDK2INSRIGF1RKMT2AKDM4E
SCHEMBL623595 0.77 MAPK1 (0.49) KMT2AKDM4EPKMNPSR1IL33
SCHEMBL626664 0.76 CDK2 (1.00) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL12505114 0.76 CDK2 (1.00) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL626665 0.76 CDK2 (1.00) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL30509894 0.76 CDK2 (1.00) CDK2INSRIGF1RGSK3AGSK3B
SCHEMBL15315401 0.75 IL33 (0.49) KMT2AKDM4EPKMNPSR1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255088-B2 Premature-termination-codons readthrough compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-02-09 US disclosed
US-20130274283-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274283-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS UPF1, NUDT21, RNGTT CDK2 960/4885INSR 4125/4885IGF1R 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.